Lipocine Inc.
As of Oct 22, 2026, Lipocine is in Stage 4, the downtrend phase, now in week 13 (since Jul 28, 2026). It closed at $1.46, 87.0% below its 52-week high and below its 200-day average, which is falling.
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is LPCN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
LPCN among Biotechnology353rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …353 | LPCN | Stage 4 · wk 13 | 23 | −31.1% |
Lipocine: quick answers
What stage is Lipocine in?
As of Oct 22, 2026, Lipocine (LPCN) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 28, 2026 and is in week 13. What the four stages mean
Is Lipocine in an uptrend?
No. Lipocine is in a Stage 4 downtrend. It trades 64.7% below its 200-day average, which is falling.
How far is Lipocine from its 52-week high?
Lipocine closed at $1.46 on Oct 22, 2026, 87.0% below its 52-week high of $11.26. Its 52-week low is $1.46.
How has Lipocine performed over the past year?
As of Oct 22, 2026, Lipocine is down 50.2% over the past year and down 81.8% so far in 2026.
Which sector and industry is Lipocine in?
Lipocine is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.